TABLE 2.
Clinical and molecular characteristics of 2009 EGFR‐negative NSCLC cases tested for ALK and ROS1 fusions and MET ex14 skipping mutation
| Characteristic | Number of cases |
|---|---|
| Age, median (range) | 63 (16–85) |
| Women | 629 (31.3%) |
| Smoking status | |
| Ever‐smoker | 407 (52.5%) |
| Never‐smoker | 368 (47.5%) |
| Unknown | 1234 |
| Histology | |
| Adenocarcinoma | 1731 (99.0%) |
| Squamous | 12 (0.7%) |
| Other | 4 (0.2%) |
| Not specified | 262 |
| ALK translocations | 107 (5.3%) |
| EML4‐ALK (E13;A20) | 49 (45.8%) |
| EML4‐ALK (E20;A20) | 14 (13.1%) |
| EML4‐ALK (E6;A20) | 41 (38.3%) |
| EML4‐ALK (E18;A20) | 3 (2.8%) |
| ROS1 translocations | 44 (2.2%) |
| CD74‐ROS1 (C6;R34) | 23 (52.3%) |
| EZR‐ROS1 (E10;R32) | 2 (4.5%) |
| EZR‐ROS1 (E10;R34) | 5 (11.4%) |
| SDC4‐ROS1 (S2;R32) | 3 (6.8%) |
| SLC34A2‐ROS1 (S13;R32) | 7 (15.9%) |
| SLC34A2‐ROS1 (S4;R32) | 1 (2.3%) |
| TPM3‐ROS1 (T8;R35) | 2 (4.5%) |
| TPM3‐ROS1 (T10;R35) a | 1 (2.3%) |
| MET ex14Δ | 31 (1.5%) |
a
This variant was initially detected as TPM3‐ROS1 (T8;R35) by real‐time PCR analysis, but further was correctly identified as TPM3‐ROS1 (T10;R35) by Sanger sequencing.